SEATTLE, June 22, 2020 (GLOBE NEWSWIRE) -- SEngine Precision Medicine,a precision oncology company revolutionizing cancer diagnostics anddrug discoveryby pre-testing drugs on patient-derivedtumor-based organoids, today presentsdataonthe predictive value ofthe PARISTestinitsposter,Organoid-based functional test to predict personalized treatment in cholangiocarcinoma(poster board #818),duringthe 2020AACRVirtualMeetingbeingheldJune 22-24, 2020.

The PARISTest is a CLIA certifiedfunctional drug assay using tumor-derived organoids. By compiling assay results, the PARIS Test generatesan actionable report to oncologists as a tool for therapeutic decisions, ranking sensitivity to targeted, endocrine and chemotherapy agents.

Dr. Astrid Margossian, M.D, Ph.D., Chief Medical Officer at SEngine, presents their poster summarizingthe strong correlation between genomics,retrospective treatment outcomes and PARISTest drug sensitivity results based on a retrospective analysis ofcholangiocarcinomapatients.The poster also highlights encouraging data on positive prospective evidence from three patients who received a PARIS Test guided treatment, each with good clinical outcome correlation. Cholangiocarcinoma is a rare type of cancer with limited therapeutic options. SEngine has demonstrated utility of the PARIS Test as a tool for oncologists to design innovative therapeutic strategies for cholangiocarcinoma patients.

In addition to SEngines poster presentation, scientific leadership at the company lead the AACR Education Session Functional Precision Medicine: Techniques, Uses and Challenges on June 23, 2020. Christopher Kemp, Ph.D., Scientific Director at SEngine Precision Medicine and full member of the Fred Hutchinson Cancer Research Center, chairs the education session. Chief Executive Officer Dr. Carla Grandori, M.D., Ph.D., presents on the strong predictive value of the PARIS Test and provides key takeaways from five years running SEngines CLIA certified organoid-based drug sensitivity assay.

Details related to the poster presentation are as follows:Title: Organoid-based functional test to predict personalized treatment in cholangiocarcinomaLead Author:AstridMargossian, M.D.,Ph.D.Senior Author: CarlaGrandori, M.D.,Ph.D.Poster Board #: 818Poster Session: Translational Research with Targeted Therapies

Details related to the education session are as follows:Education Session: Functional Precision Medicine: Techniques, Uses and ChallengesChair: Christopher Kemp, Ph.D.Invited Speaker: Carla Grandori, M.D., Ph.D.Talk Title: Predictive value and lessons learned from the PARIS Test: a CLIA certified drug sensitivity assay employing patient-derived tumor organoids

About the PARIS TestThe PARISTest is based on the capability to propagate patient-specific cancercellsas organoidsoutside the bodyand is applicable to all solid tumorsincluding colon, breast, lung, ovarian and pancreatic cancer. Organoids are cancer-derived cells grownin 3D outside the body, which maintain the functionality of the original tumor as well as its genomic characteristics.For cancerswherea treatmentpath is not clear, such asmany metastatic and recurrent cancers,the PARIS Test provides crucial information to thetreating physicianstomatch the right drug to the right patient.

AboutSEnginePrecision MedicineSEnginePrecision Medicine Inc. is a precision oncology company revolutionizing cancer diagnostics and therapies by pre-testing drugs on patient-derived organoids grown ex-vivo utilizing patient specific tumor cells.As a spin-out from the world-renowned Fred Hutchinson Cancer ResearchCenter,SEngineis leveraging over two decades of R&D in diagnostics and drug discovery. The Company is commercializingthePARISTest, a next generation diagnostic test that predicts drug responses integrating knowledge of cancer genomics with organoids, robotics, and AI-driven computational tools.SEnginesCLIA certified PARISTest generates predictive drug sensitivity reports for patients with solid tumors.SEngineis also pursuing drug discovery via strategic collaborations with biopharmaceutical / pharma companies leveraging its precision oncology platform.

Discover more atSengineMedicine.comand follow the latest news fromSEngineon Twitter at@SEngineMedicineand onLinkedIn.

Contact:

Stephanie Carringtonstephanie.carrington@westwicke.com646-277-1282

See the original post here:

SEngine Precision Medicine Presents Innovative Data on the CLIA Certified PARIS Test for Oncology Drug Sensitivity and the Future of Functional...